Separate terms with OR to return results that match either term.
 
Clear All

9,752 Matching ResultsExport these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category (Ascending) Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
70771-1691-01 70771-1691 Pemetrexed disodium Pemetrexed 100.0 mg/4mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous May 26, 2022 In Use
70771-1692-01 70771-1692 Pemetrexed disodium Pemetrexed 500.0 mg/20mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous May 26, 2022 In Use
70771-1693-01 70771-1693 Pemetrexed disodium Pemetrexed 1000.0 mg/40mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous May 26, 2022 In Use
70771-1708-01 70771-1708 BORTEZOMIB BORTEZOMIB 1.0 mg/mL Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous May 2, 2022 In Use
70860-0202-10 70860-0202 Pemetrexed disodium Pemetrexed 100.0 mg/4.2mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous May 25, 2022 In Use
70860-0203-50 70860-0203 Pemetrexed disodium Pemetrexed 500.0 mg/20mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous May 25, 2022 In Use
70860-0225-10 70860-0225 Bortezomib Bortezomib 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous May 6, 2022 In Use
72078-0040-08 72078-0040 DOCETAXEL ANHYDROUS Docetaxel 10.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Sept. 28, 2018 In Use
81643-9270-01 81643-9270 Floxuridine Floxuridine 500.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intra-arterial June 9, 2022 In Use
63539-0117-01 63539-0117 Bosutinib monohydrate, Bosutinib Bosulif 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 4, 2012 In Use
76388-0635-25 76388-0635 Chlorambucil Leukeran 2.0 mg/1 Chemotherapy Alkylating Agent Nitrogen Mustard Oral Feb. 13, 1985 Sept. 30, 2023 In Use
76388-0635-50 76388-0635 Chlorambucil Leukeran 2.0 mg/1 Chemotherapy Alkylating Agent Nitrogen Mustard Oral Feb. 13, 1985 Oct. 31, 2017 In Use
76388-0713-25 76388-0713 Busulfan Myleran 2.0 mg/1 Chemotherapy Alkylating Agent Alkylsulfonate Oral March 21, 1985 June 30, 2023 In Use
76388-0880-25 76388-0880 Thioguanine Tabloid 40.0 mg/1 Chemotherapy Antimetabolite Purine Analog Oral March 12, 2013 March 31, 2025 In Use
00078-0683-06 00078-0683 Nelarabine Arranon 5.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Oct. 5, 2016 In Use
00078-0683-61 00078-0683 Nelarabine Arranon 5.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Aug. 2, 2019 In Use
65162-0843-06 65162-0843 Capecitabine Capecitabine 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral March 10, 2017 Feb. 1, 2024 In Use
65162-0844-06 65162-0844 Capecitabine Capecitabine 500.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral March 10, 2017 Feb. 1, 2024 In Use
65162-0844-16 65162-0844 Capecitabine Capecitabine 500.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral March 10, 2017 Feb. 1, 2024 In Use
65162-0844-50 65162-0844 Capecitabine Capecitabine 500.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral March 10, 2017 Feb. 1, 2024 In Use
00409-1062-01 00409-1062 Pemetrexed Pemetrexed 25.0 mg/mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous June 20, 2022 In Use
45629-0089-01 45629-0089 Tivozanib FOTIVDA 0.89 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral March 10, 2021 In Use
45629-0134-01 45629-0134 Tivozanib FOTIVDA 1.34 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral March 10, 2021 In Use
45963-0613-53 45963-0613 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous July 19, 2018 July 31, 2022 No Longer Used
45963-0613-56 45963-0613 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous July 19, 2018 April 30, 2021 No Longer Used
45963-0613-59 45963-0613 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous July 19, 2018 June 30, 2022 No Longer Used
45963-0613-83 45963-0613 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous June 13, 2018 April 30, 2021 No Longer Used
45963-0613-86 45963-0613 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous June 13, 2018 March 31, 2021 No Longer Used
45963-0613-89 45963-0613 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous June 13, 2018 Aug. 31, 2021 No Longer Used
49884-0119-91 49884-0119 Everolimus Everolimus 2.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Dec. 10, 2019 In Use
49884-0125-91 49884-0125 Everolimus Everolimus 5.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Dec. 10, 2019 In Use
49884-0127-91 49884-0127 Everolimus Everolimus 7.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Dec. 10, 2019 In Use
59923-0701-00 59923-0701 Epirubicin Hydrochloride Epirubicin Hydrochloride 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous May 19, 2014 In Use
59923-0701-25 59923-0701 Epirubicin Hydrochloride Epirubicin Hydrochloride 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous May 19, 2014 In Use
66530-0249-40 66530-0249 Fluorouracil Fluorouracil 50.0 mg/g Chemotherapy Antimetabolite Pyrimidine Analog Topical April 11, 2008 Aug. 31, 2022 No Longer Used
71258-0015-02 71258-0015 iobenguane I-131 Azedra 15.0 mCi/mL Chemotherapy Radiopharmaceutical I 131 Intravenous July 30, 2018 In Use
71258-0015-22 71258-0015 iobenguane I-131 Azedra 15.0 mCi/mL Chemotherapy Radiopharmaceutical I 131 Intravenous July 30, 2018 In Use
73657-0020-01 73657-0020 melphalan flufenamide Pepaxto 20.0 mg/50mL, 20.0 mg/50mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Feb. 26, 2021 Aug. 13, 2022 No Longer Used
00143-9098-01 00143-9098 Bortezomib Bortezomib 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous July 27, 2022 In Use
00143-9135-01 00143-9135 Mitomycin Mitomycin 20.0 mg/1 Chemotherapy Antitumor Antibiotic Alkylating Agent/ Mitomycin Intravenous Oct. 1, 2022 In Use
00310-3512-60 00310-3512 Acalabrutinib CALQUENCE 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BTK Oral Aug. 4, 2022 In Use
00310-3512-95 00310-3512 Acalabrutinib CALQUENCE 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BTK Oral Aug. 4, 2022 In Use
00338-0720-01 00338-0720 PEMETREXED PEMETREXED 100.0 mg/10mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Aug. 18, 2022 In Use
00409-1700-01 00409-1700 Bortezomib Bortezomib 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous July 27, 2022 In Use
16729-0522-05 16729-0522 Pemetrexed disodium Pemetrexed 25.0 mg/mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Sept. 8, 2022 In Use
16729-0522-28 16729-0522 Pemetrexed disodium Pemetrexed 25.0 mg/mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Sept. 8, 2022 In Use
16729-0522-35 16729-0522 Pemetrexed disodium Pemetrexed 25.0 mg/mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Sept. 8, 2022 In Use
16729-0522-64 16729-0522 Pemetrexed disodium Pemetrexed 25.0 mg/mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Sept. 8, 2022 In Use
10135-0702-01 10135-0702 Hydroxyurea Hydroxyurea 500.0 mg/1 Chemotherapy Miscellaneous Agent Antimetabolite/Organooxygen Oral Jan. 28, 2022 In Use
00781-3258-70 00781-3258 Bortezomib Bortezomib 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous May 31, 2022 In Use

Found 9,752 results in 10 millisecondsExport these results